c-jun末端激酶在亚砷酸钠致人胚胎肝细胞损伤中的表达

目的探讨亚砷酸钠染毒对人胚胎肝(L-02)细胞中c-jun末端激酶(JNK)的变化。方法将处于对数生长期的L-02细胞分别暴露于终浓度为0(对照)、50、100、150μmol/L的亚砷酸钠溶液中培养24 h,采用四甲基偶氮唑蓝(MTT)法检测细胞生长情况,采用流式细胞术检测染毒24 h时的细胞周期及细胞凋亡率;采用蛋白杂交(Western-blot)法检测JNK及p-JNK的蛋白表达水平。结果与对照组相比,各浓度亚砷酸钠染毒组L-02细胞的存活率及G0-G1期构成比均较低,JNK、p-JNK的蛋白表达水平和S期构成比及凋亡率均较高;而G2-M期构成比在50μmol/L亚砷酸钠染毒组较低,在100、150μmol/L亚砷酸钠染毒组均较高,差异均有统计学意义(P0.05)。且随着亚砷酸钠染毒浓度的升高,L-02细胞凋亡率及JNK和p-JNK蛋白的表达水平均呈上升趋势,细胞存活率呈下降趋势。结论亚砷酸钠诱导L-02细胞凋亡可能与JNK及p-JNK表达的增加有关。     

基于厚度特征模糊C均值算法的膀胱肿瘤疑似区域三维分割方法研究

目的:使用模糊C均值算法对膀胱壁厚度特征进行聚类,有效地分割出三维膀胱肿瘤疑似区域。方法:获取膀胱MRI数据,应用Level Set分割算法对膀胱内、外壁进行分割,然后计算膀胱壁的三维厚度,通过对膀胱壁厚度聚类得到三维肿瘤疑似区域。结果:由该方法分割得到的疑似区域比较准确,与临床放射医师勾画的肿瘤区域有90%以上的重叠率。结论:该方法可有效地分割出三维膀胱肿瘤疑似区域,具有一定的有效性,但尚需要采集更多的数据来进行验证。     

小肠结肠炎耶尔森菌在中国家畜家禽间分布的研究

目的为了解中国小肠结肠炎耶尔森菌在不同家畜、家禽中的分布规律,对不同地区家畜、家禽进行带菌状况调查。方法采集中国不同地区家畜、家禽咽拭子,肛拭子和粪便标本进行小肠结肠炎耶尔森菌分离培养,并对分离到的菌株进行血清分型、生物分型及毒力相关基因检测。结果猪中小肠结肠炎耶尔森菌携带率最高为12.91%,其次为犬,携带率为9.80%,两者分离的致病性菌株所占比例分别为73.50%和59.44%。而其他动物中小肠结肠炎耶尔森菌携带率较低,鸡、牛和羊分别为4.50%、2.78%和0.89%,且主要以非致病性菌株为主,分别占100%、94.44%和93.33%。结论首次在中国进行大规模家畜、家禽中小肠结肠炎耶尔森菌分布调查。动物中小肠结肠炎耶尔森菌感染率存在较大物种差异和地域性分布特征,猪、犬是小肠结肠炎耶尔森菌的主要储存宿主和传染源,而牛、羊、鸡、鸭等主要携带非致病性小肠结肠炎耶尔森菌,属于偶然宿主。     

医学专用输入引擎的设计与应用研究

目的:研究探讨医学专用输入引擎的设计方法和应用效果。方法:在目前广泛使用的拼音、五笔字型汉字编码输入法的基础上,增加各种医学信息代码及国家标准代码数据集的录入、提示功能,将医院信息化中涉及的大量医学信息标准和规范进行系统有序的整理、规划和实施。结果:实现了统一标准代码术语与专业数据组的XML文档生成。结论:医学专用输入引擎的设计与应用,实现了实时地与医院各应用系统交互、传递所录入的标准数据集信息,为将来实现医疗卫生领域业务应用系统的互联互通和信息共享提供了数据基础。     

重组人生长激素对身材矮小儿童增高疗效的相关影响因素分析

目的探讨重组人生长激素对矮小症患儿身高增长的影响因素,为进一步制定重组人生长激素(recombinant human growth hormone,rhGH)治疗方案提供依据。方法以rhGH治疗时间超过6个月~2年的103例矮小症患儿为对象,将治疗后身高增长(Y)设为因变量,以年龄,身高,体重,靶身高,身高标准差分值,骨龄,父亲身高,母亲身高,实际年龄(CA)-骨龄(bone age,BA),BA/CA,生长激素峰值,治疗时间和诊断作为自变量,采用多元逐步回归分析,评价影响rhGH治疗对身高增长疗效的因素。结果多元线性回归分析结果显示,rhGH治疗后身高增长与治疗前患儿身高呈负相关,与治疗时间,遗传靶身高,父亲身高,BA与CA的差值与疗效呈正相关。结论骨龄落后的程度、开始治疗时身高、靶身高可作为预测rhGH增高疗效的指标之一。     

己烯雌酚对大鼠CYP2C6和CYP2D2酶的体外抑制作用

目的研究己烯雌酚对大鼠肝微粒体中细胞色素P450同工酶2C6(CYP2C6)和2D2(CYP2D2)的抑制作用。方法采用探针底物法,使用液相色谱-串联质谱检测在不同浓度的己烯雌酚孵育体系中,CYP2C6和CYP2D2的特征性底物双氯芬酸与右美沙芬产生的代谢产物4’-羟基双氯芬酸与右啡烷的浓度。计算得到己烯雌酚对CYP2C6与CYP2D2的半数抑制浓度(IC50)。结果己烯雌酚对大鼠CYP2C6与CYP2D2的IC50值分别为(5.31±0.06)μmol/L,(7.03±0.01)μmol/L。结论己烯雌酚对大鼠CYP2C6与CYP2D2具有中等抑制作用,有必要进一步在体外人体水平对其进行评价以预防潜在的临床药物相互作用。     

鲁登巴赫综合征的外科治疗

目的 :回顾分析 10例鲁登巴赫综合征 ,探讨该疾病在病理生理、诊断和治疗方面的特点。方法 :总结经外科治疗的鲁登巴赫综合征共 10例患者的临床资料。结果 :全组病例无围手术期死亡 ,无顽固性心力衰竭、肺动脉高压危象及恶性心律失常发生。结论 :鲁登巴赫综合征应及早手术治疗 ,修补房间隔缺损同时有效的解除二尖瓣狭窄 ,探查并处理合并的三尖瓣关闭不全 ,术后积极治疗肺动脉高压 ,支持心功能 ,可以取得满意的手术效果     

Safety and efficacy of a 6 French perclose arterial suturing device following percutaneous coronary interventions: a pilot evaluation

BACKGROUND: Arterial access site management after percutaneous coronary intervention (PCI) is a matter of increasing importance in this era of potent antiplatelet pharmacotherapy. We evaluated the safety and efficacy of a 6 French (Fr) Perclose suturing device in achieving rapid hemostasis of the access site after PCI and thus improving patient comfort. METHODS: The 6 Fr Perclose (Prostar) device consists of a suture-based closure device delivered via introducer sheath designed for suturing of the arteriotomy puncture site. Over a 3-month period, the device was used in 48 consecutive PCI treated patients (age, 62 13 years; 70% male; 44% post myocardial infarction) and in-hospital groin complication rate was compared to 48 consecutive patients (age, 64 12 years; 64% male; 33% post myocardial infarction) who had manual compression hemostasis. RESULTS: Antiplatelet glycoprotein IIb/IIIa antagonists were used more frequently during and following the procedure in 58% of Perclose-treated patients versus 42% of the manual compression group (p = 0.019). Leg immobilization duration was 3 4 hours in all patients sutured by the device; in patients with manual compression, the sheath was removed at an average of 4.8 2.5 hours after termination of the PCI and an additional 6 hours of leg immobilization were subsequently required. No difference in overall major complication rate was found between groups (6.2% in suture-mediated patients versus 9.3% in manual compression group; p = 0.60). In 3 patients (6.2%) treated using the device, adjunctive manual compression was required in addition to groin suturing due to technical failure or residual oozing from the arteriotomy site. CONCLUSION: The 6 Fr Perclose device can be safely used to achieve rapid hemostasis and the device may hasten bed mobilization of PCI-treated patients despite frequent use of potent antiplatelet pharmacotherapy during coronary interventions.     

The efficacy and safety of Batroxobin in combination with anticoagulation on cerebral venous sinus thrombosis

Cerebral venous sinus thrombosis (CVST) is an uncommon subtype of stroke with highly variable clinical presentation. Although anticoagulation with heparin and/or warfarin remains the standard treatment for CVST, treatment failure is still common. This study aims to evaluate the safety and efficacy of Batroxobin in combination with anticoagulation on CVST control. In this retrospective study, a total of 61 CVST patients were enrolled and divided into Batroxobin (n?=?23) and control (n?=?38) groups. In addition to the same standard anticoagulation in control, patients in the treatment group received Batroxobin 5 BU intravenous infusion (10 BU for the first time) every other day, for a total of three infusions. A higher recanalization rate was found in Batroxobin group (adjusted OR [95% CI] of 2.5 [1.1–5.0], p?=?0.028) compared to the control group, especially in patients with high levels of fibrinogen (adjusted OR [95% CI] of 4.7 [1.4–16.7], p?=?0.015). Statistically significant differences between the two groups were seen regarding the levels of thrombin time, fibrinogen and d-dimer at each cut-off time point (all p?<?0.01). Compared with baseline, NIHSS scores at discharge showed significant improvement in the Batroxobin group [0(0, 4.25)–5(2, 11), p?=?0.036]. No significant difference in mRS scores was found between the two groups at discharge or at 6-month outpatient follow-up (all p?>?0.05). Additionally, Batroxobin did not increase the risk of intracranial hemorrhage. We conclude that Batroxobin is a potentially safe and effective adjunct therapeutic agent promoting CVST recanalization especially in patients with high level of fibrinogen.     

天津地区奶牛感染隐孢子虫情况的调查

目的调查天津市周边区县奶牛隐孢子虫感染情况。方法对5处奶牛粪样进行检查，采用改良抗酸染色法初筛，对检出的可疑阳性样本采用金胺-酚染色、金胺酚-改良抗酸染色、蔗糖不连续梯度离心法及饱和硫酸锌漂浮等方法进一步观察确定。结果个体养殖户奶牛粪检隐孢子虫阳性率西青区为8.33%（3/36），东丽区为70.00%（7/10），津南区为6.67%（1/15）。中型奶牛场奶牛粪样75份，其中武清县35份，蓟县40份，均为阴性。检出的隐孢子虫经初步鉴定分别为鼠隐孢子虫与微小隐孢子虫。结论天津地区奶牛有一定程度的隐孢子虫感染，需进一步加强小型养牛户的卫生防疫。